MSH2 and cancer: Somatic CpG hypermutation and biallelic inactivation were observed for MSH2 (5/76 tumours) and MSH6 (11/76 tumours), supporting a strong genetic association between MutSα-deficiency and somatic CpG hypermutation across cancer types.